Researchers at Wichita State University are developing a novel nano-composite drug delivery system to potentially treat inflammation, such as arthritis, and cancer through targeted delivery of slowly released therapeutic agents to the affected region. In-vivo results have shown that the drug delivery system is localized (or concentrated) in the targeted region, and therapeutic effects were readily observed. In vitro and in-vivo experiments have shown that the drug delivery carriers do not provoke much foreign body responses or inflammation, even at high concentrations. Experimental results have confirmed an extended release rate of therapeutic agent, the enhanced cytotoxic influence to target cells, and an ability to guide the drug carrier system to the desired location.
The novel magnetic targeted drug delivery design plus the addition of the protein composite may naturally move towards areas of inflammation. Thus, the drug delivery system (DDS) will require less magnetic material than common methods that could cause inflammation or harm to tissues.
Proteins are well known to aid in diffusion from the lungs to the blood system, thus this DDS could be an effective method of drug delivery from the lungs to the blood.
- For patients with ailments such as arthritis or cancer.
- A new drug delivery system
- Available for license and pending-patent
- Potential for ongoing collaboration with inventors and Wichita State University researchers.
- Patent Status: Pending